Cabaletta Bio Inc., a clinical-stage biotechnology company specializing in targeted cell therapies for autoimmune diseases, announced the commencement of an underwritten public offering of its common stock and accompanying warrants. The offering includes pre-funded warrants for certain investors, allowing the purchase of common stock. Cabaletta plans to grant underwriters a 30-day option to purchase up to an additional 15% of the offered shares and warrants. Jefferies, TD Cowen, and Cantor are serving as joint book-running managers for the offering, which is contingent upon market conditions and expected to close on or about June 12, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.